Yuequan Shi

Peking Union Medical College Hospital, Peking Union Medical College
Beijing, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 29 publications

Sensitivity of different epidermal growth factor receptor (EGFR) exon 19 deletion subtypes to first-line osimertinib in Chinese non-small cell lung cancer patients.

Sensitivity of different epidermal growth factor receptor (EGFR) exon 19 deletion subtypes to first-line osimertinib in Chinese non-small cell lung cancer patients.

Journal: BMC cancer

Published: November 13, 2025

Alectinib versus crizotinib as the first-line treatment in patients with advanced ALK-positive non-small cell lung cancer: a Chinese real-world cohort study.

Alectinib versus crizotinib as the first-line treatment in patients with advanced ALK-positive non-small cell lung cancer: a Chinese real-world cohort study.

Journal: Translational lung cancer research

Published: September 30, 2025

Clinical outcomes and predictive factors of immunotherapy efficacy in non-small-cell lung cancer brain metastases: a comparative study.

Clinical outcomes and predictive factors of immunotherapy efficacy in non-small-cell lung cancer brain metastases: a comparative study.

Journal: BMC cancer

Published: September 22, 2025

Letter Re: Lung cancer detection by electronic nose analysis of exhaled breath: a multi-center prospective external validation study.

Letter Re: Lung cancer detection by electronic nose analysis of exhaled breath: a multi-center prospective external validation study.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: April 05, 2025

Comparative effectiveness of pembrolizumab-chemotherapy versus chemotherapy with/without bevacizumab in unresectable, locally advanced or metastatic non-small cell lung cancer: a Chinese multicenter real-world analysis emphasizing PD-L1-negative populations.

Comparative effectiveness of pembrolizumab-chemotherapy versus chemotherapy with/without bevacizumab in unresectable, locally advanced or metastatic non-small cell lung cancer: a Chinese multicenter real-world analysis emphasizing PD-L1-negative populations.

Journal: Translational lung cancer research

Published: March 08, 2025

Prognostic Role of Early Dynamic Changes in Neutrophil-to-Lymphocyte Ratio of Nonsmall Cell Lung Cancer Patients.

Prognostic Role of Early Dynamic Changes in Neutrophil-to-Lymphocyte Ratio of Nonsmall Cell Lung Cancer Patients.

Journal: Journal of immunotherapy (Hagerstown, Md. : 1997)

Published: January 21, 2025

Programmed death-ligand 1 tumor proportion score in predicting the safety and efficacy of PD-1/PD-L1 antibody-based therapy in patients with advanced non-small cell lung cancer: A retrospective, multicenter, observational study.

Programmed death-ligand 1 tumor proportion score in predicting the safety and efficacy of PD-1/PD-L1 antibody-based therapy in patients with advanced non-small cell lung cancer: A retrospective, multicenter, observational study.

Journal: Chinese medical journal

Published: June 13, 2024

Pure Red Cell Aplasia Secondary to Parvovirus B19 Infection as a Rare Cause of Anemia in a Dialysis Patient.

Pure Red Cell Aplasia Secondary to Parvovirus B19 Infection as a Rare Cause of Anemia in a Dialysis Patient.

Journal: Internal medicine (Tokyo, Japan)

Published: February 18, 2024

Current clinical practice and physicians' insights on Chinese patients with advanced non-small cell lung cancer habouring epidermal growth factor receptor 20 insertion mutation.

Current clinical practice and physicians' insights on Chinese patients with advanced non-small cell lung cancer habouring epidermal growth factor receptor 20 insertion mutation.

Journal: BMC cancer

Published: September 11, 2023

Osimertinib versus comparator first-generation epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in patients with advanced EGFR-mutated non-small cell lung cancer: a Chinese, multicenter, real-world cohort study.

Osimertinib versus comparator first-generation epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in patients with advanced EGFR-mutated non-small cell lung cancer: a Chinese, multicenter, real-world cohort study.

Journal: Translational lung cancer research

Published: September 06, 2023

Clinical significance of DNA damage response mutations in stage I and stage IIIa NSCLC.

Clinical significance of DNA damage response mutations in stage I and stage IIIa NSCLC.

Journal: Thoracic cancer

Published: June 26, 2023

Circulating tumor cells PD-L1 expression detection and correlation of therapeutic efficacy of immune checkpoint inhibition in advanced non-small-cell lung cancer.

Circulating tumor cells PD-L1 expression detection and correlation of therapeutic efficacy of immune checkpoint inhibition in advanced non-small-cell lung cancer.

Journal: Thoracic cancer

Published: August 31, 2022

Showing 1-12 of 29

Last Updated: 09/26/2026